Your browser doesn't support javascript.
loading
ClC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation.
Imbrici, P; Maggi, L; Mangiatordi, G F; Dinardo, M M; Altamura, C; Brugnoni, R; Alberga, D; Pinter, G Lauria; Ricci, G; Siciliano, G; Micheli, R; Annicchiarico, G; Lattanzi, G; Nicolotti, O; Morandi, L; Bernasconi, P; Desaphy, J-F; Mantegazza, R; Camerino, D Conte.
Afiliação
  • Imbrici P; Department of Pharmacy - Drug Sciences, University of Bari, Bari, Italy.
  • Maggi L; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico 'Carlo Besta', Milano, Italy.
  • Mangiatordi GF; Department of Pharmacy - Drug Sciences, University of Bari, Bari, Italy.
  • Dinardo MM; Department of Pharmacy - Drug Sciences, University of Bari, Bari, Italy.
  • Altamura C; Department of Pharmacy - Drug Sciences, University of Bari, Bari, Italy.
  • Brugnoni R; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico 'Carlo Besta', Milano, Italy.
  • Alberga D; Department of Physics 'M. Merlin', INFN and TIRES, University of Bari, Bari, Italy.
  • Pinter GL; Neuroalgology and Headache Unit, IRCCS Fondazione Istituto Neurologico 'Carlo Besta', Milano, Italy.
  • Ricci G; Department of Clinical and Experimental Medicine, Section of Neurology, University of Pisa, Pisa, Italy.
  • Siciliano G; Department of Clinical and Experimental Medicine, Section of Neurology, University of Pisa, Pisa, Italy.
  • Micheli R; Unit of Child Neurology and Psychiatry, Spedali Civili, Brescia, Italy.
  • Annicchiarico G; Regional Coordination for Rare Diseases, A. Re. S. Puglia, Bari, Italy.
  • Lattanzi G; Department of Physics 'M. Merlin', INFN and TIRES, University of Bari, Bari, Italy.
  • Nicolotti O; Department of Pharmacy - Drug Sciences, University of Bari, Bari, Italy.
  • Morandi L; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico 'Carlo Besta', Milano, Italy.
  • Bernasconi P; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico 'Carlo Besta', Milano, Italy.
  • Desaphy JF; Department of Pharmacy - Drug Sciences, University of Bari, Bari, Italy.
  • Mantegazza R; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico 'Carlo Besta', Milano, Italy.
  • Camerino DC; Department of Pharmacy - Drug Sciences, University of Bari, Bari, Italy.
J Physiol ; 593(18): 4181-99, 2015 Sep 15.
Article em En | MEDLINE | ID: mdl-26096614
ABSTRACT
KEY POINTS Loss-of-function mutations of the skeletal muscle ClC-1 channel cause myotonia congenita with variable phenotypes. Using patch clamp we show that F484L, located in the conducting pore, probably induces mild dominant myotonia by right-shifting the slow gating of ClC-1 channel, without exerting a dominant-negative effect on the wild-type (WT) subunit. Molecular dynamics simulations suggest that F484L affects the slow gate by increasing the frequency and the stability of H-bond formation between E232 in helix F and Y578 in helix R. Three other myotonic ClC-1 mutations are shown to produce distinct effects on channel function L198P shifts the slow gate to positive potentials, V640G reduces channel activity, while L628P displays a WT-like behaviour (electrophysiology data only). Our results provide novel insight into the molecular mechanisms underlying normal and altered ClC-1 function. ABSTRACT Myotonia congenita is an inherited disease caused by loss-of-function mutations of the skeletal muscle ClC-1 chloride channel, characterized by impaired muscle relaxation after contraction and stiffness. In the present study, we provided an in-depth characterization of F484L, a mutation previously identified in dominant myotonia, in order to define the genotype-phenotype correlation, and to elucidate the contribution of this pore residue to the mechanisms of ClC-1 gating. Patch-clamp recordings showed that F484L reduced chloride currents at every tested potential and dramatically right-shifted the voltage dependence of slow gating, thus contributing to the mild clinical phenotype of affected heterozygote carriers. Unlike dominant mutations located at the dimer interface, no dominant-negative effect was observed when F484L mutant subunits were co-expressed with wild type. Molecular dynamics simulations further revealed that F484L affected the slow gate by increasing the frequency and stability of the H-bond formation between the pore residue E232 and the R helix residue Y578. In addition, using patch-clamp electrophysiology, we characterized three other myotonic ClC-1 mutations. We proved that the dominant L198P mutation in the channel pore also right-shifted the voltage dependence of slow gating, recapitulating mild myotonia. The recessive V640G mutant drastically reduced channel function, which probably accounts for myotonia. In contrast, the recessive L628P mutant produced currents very similar to wild type, suggesting that the occurrence of the compound truncating mutation (Q812X) or other muscle-specific mechanisms accounted for the severe symptoms observed in this family. Our results provide novel insight into the molecular mechanisms underlying normal and altered ClC-1 function.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canais de Cloreto / Mutação / Miotonia Congênita Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canais de Cloreto / Mutação / Miotonia Congênita Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article